Lexicon Pharmaceuticals (LXRX) Jefferies 2024 Global Healthcare Conference summary

Pipeline and clinical milestones

• INPEFA, a dual SGLT1/2 inhibitor, is approved for heart failure and is expected to see accelerated launch in the second half of the year as broader access is achieved.

• NDA resubmission for sotagliflozin in Type 1 diabetes is planned around mid-year, with a six-month review cycle and potential launch in 2025.

• Phase III study for sotagliflozin in hypertrophic cardiomyopathy (HCM) will begin enrolling mid-year, targeting data readout in 2026.

• LX9211 is in a 400-patient phase II-B dose optimization study for diabetic peripheral neuropathic pain, with data expected in the first half of next year.

• A new obesity candidate targeting ACSL5 is entering IND-enabling studies, aiming for clinical entry within a year.

Commercial strategy and market opportunity

• INPEFA net sales exceeded $1 million in Q1, with growth expected as payer access improves and utilization management is reduced.

• The heart failure market is large, with over 7 million U.S. patients and significant growth potential; INPEFA is included in treatment guidelines.

• Separate branding and differentiated pricing are planned for Type 1 diabetes, while HCM pricing is expected to align with heart failure.

• The sales force for heart failure consists of 150 reps; a more modest, focused team will address endocrinology for Type 1 diabetes, leveraging existing infrastructure.

Product differentiation and competitive landscape

• INPEFA is distinguished by dual SGLT1/2 inhibition, showing a 50% reduction in 30-day readmissions and benefits in MI and stroke not seen with SGLT2 inhibitors.

• Sotagliflozin's SGLT1 inhibition provides glycemic benefits in Type 1 diabetes, especially for patients with chronic kidney disease, where SGLT2 efficacy declines.

• LX9211's pain studies use stable patient populations, aligning with real-world use and differentiating from competitors like Vertex.